HOUSTON, Feb. 27, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, today announced the Company's Chief
Executive Officer John Climaco will
ring the opening bell of The Nasdaq Stock Market on Tuesday, March 3, 2020, at 9:30 a.m. Eastern time.
"We are honored to be ringing the Nasdaq opening bell to
celebrate our initial public offering, which we closed late last
year," said Mr. Climaco. "Since going public we have made
significant progress in preparing the Investigational New Drug
application for our lead drug candidate Berubicin to treat
glioblastoma multiforme, an aggressive brain cancer. In addition,
we added to our clinical program a second drug candidate, WP1244, a
novel DNA binding agent. I want to thank our employees, directors,
clinical advisors and shareholders for supporting our mission to be
a leading developer of organ-targeted cancer therapeutics."
To view a live stream of the Nasdaq Opening Bell ceremony,
please visit Nasdaq's MarketSite here.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
trial with Berubicin in GBM which Reata conducted in 2006. In
this trial, 44% of patients experienced a statistically significant
improvement in progression-free survival. This 44% disease control
rate was based on 11 patients (out of 25 evaluable patients) with
stable disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of February 20, 2020. In the second half of 2020,
CNS expects to commence a Phase 2 clinical trial of Berubicin for
the treatment of GBM in the U.S., while a sub-licensee partner
undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial
in pediatric GBM patients in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has shown in
preclinical studies that it is 500-times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
proliferation.
Forward-Looking Statements
Some of the statements in
this press release are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to prepare
the Investigational New Drug application for its lead drug
candidate Berubicin to treat glioblastoma multiforme. These
statements relate to future events, future expectations, plans and
prospects. Although CNS believes the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
CNS has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties and other factors, including those discussed
in the Company's SEC filings, including under the heading "Risk
Factors" in the Form S-1 filed on October 7,
2019. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-ring-nasdaq-stock-market-opening-bell-on-march-3-301011658.html
SOURCE CNS Pharmaceuticals, Inc.